Citation Tools
PDFRegular and young investigator award abstracts
Clinical trials in progress
421 Initial results of a phase 1 trial of RP2, a first in class, enhanced potency, anti-CTLA-4 antibody expressing, oncolytic HSV as single agent and combined with nivolumab in patients with solid tumors
Download to a citation manager
Download the citation for this article by clicking on one of the following citation managers:
- Cite this article as:
- 421 Initial results of a phase 1 trial of RP2, a first in class, enhanced potency, anti-CTLA-4 antibody expressing, oncolytic HSV as single agent and combined with nivolumab in patients with solid tumors